BMJ가 기사에서 신종플루 백신 이익에 대해 잘못된 통계를 인용한 것에 대해 사과했다고 합니다. JP모건은 69억 달러 어치의 신종플루 백신이 판매될 것으로 예상했으나, 유럽제약산업협의회(EFPIA) 홈페이지에 게재된 통계에 따르면 25억 달러 어치의 신종플루 백신이 판매되었다고 합니다.
Apology from the BMJ for erroneous flu vaccine profits allegation
출처 : The Pharma Letter Article | 6 July 2010
http://www.thepharmaletter.com/file/96423/apology-from-the-bmj-for-erroneous-flu-vaccine-profits-allegation.html
The British Medical Journal has published a correction and apology for the use of incorrect figures in its expose on whether advisors to the World Health Organization had a conflict of interest in so far as they had financial ties to drugmakers (The Pharma Letter June 7).
Fiona Godlee, editor-in-chief of the BMJ, conceded that she was quoting from the Council of Europe report which itself was quoting a JP Morgan report that estimated total sales (not profit as she stated) for pandemic vaccine and adjuvant, and was $6.9 billion. The industry’s audited accounts for 2009 give sales figures for pandemic vaccine in 2009 in the region of $2.5 billion, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) web site.
The JP Morgan figures quoted in a TPL (June 10 issue) story on the issue said that producers of pandemic vaccines had so far “netted” an estimated $7-$10 billion from government orders, so not implying this was profit.
Apparently, Ms Godlee took the numbers not directly from the JP Morgan report, but from the Council of Europe report, which had in turn quoted “incorrectly” from the JP Morgan report, declaring that industry sales figures were profits.
The EFPIA posting says that is worth noting a quote from the author of the Council of Europe report – Member of the European Parliament Paul Flynn (UK, SOC) – on his blog referring to the press conference he gave with the BMJ: “We have never met before but we cooed in harmony and just avoided saying it was the Pharmas that did it.” This “tells us a great deal about Mr Flynn’s attitude towards the pharmaceutical industry,” the EFPIA commented.
An industry insider told TPL in a personal capacity: “I don’t want to be too critical of BMJ, but [Ms Godlee’s] closeness to Paul Flynn, a severe critic of the industry (and her decision not to check the facts from the primary source) does not reinforce an impression of objectivity on the industry.
